TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD).
Latest Information Update: 04 Jul 2023
At a glance
- Drugs Otelixizumab (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- Acronyms TTEDD
- Sponsors GlaxoSmithKline; GSK
- 11 Oct 2017 Status changed to discontinued.
- 17 Feb 2012 Actual end date Dec 2011 added as reported by ClinicalTrials.gov.
- 30 Sep 2011 Association GlaxoSmithKline added as reported by ClinicalTrials.gov.